3-氟-4-甲基苯乙酸 | 261951-74-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-4-甲基苯乙酸
• 中文别名: 2-(3-氟-4-甲基苯基)乙酸
• 英文名称: 2-(3-fluoro-4-methylphenyl)acetic acid
• 英文别名: 3-Fluoro-4-methylphenylacetic acid
• CAS: 261951-74-0
• 化学式: C₉H₉FO₂
• 分子量: 168.168
• InChiKey: YECYDEGFKJWADM-UHFFFAOYSA-N

物化性质

• 熔点：
  104-107℃
• 沸点：
  272.3±25.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-氟-4-甲基苯乙酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(3-fluoro-4-methylphenyl)acetyl chloride
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848
• 作为产物：
  描述：

  3-氟-4-甲基苯硼酸 在 potassium phosphate 、 三(1-萘基)膦 、 水 、 palladium diacetate 、 lithium hydroxide 作用下， 以 水 为溶剂， 生成 3-氟-4-甲基苯乙酸
  参考文献：
  名称：

  Structure–Activity Relationship Studies of the Aryl Acetamide Triazolopyridazines against Cryptosporidium Reveals Remarkable Role of Fluorine

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c00110

文献信息

• Enantioselective Construction of Quaternary All-Carbon Centers via Copper-Catalyzed Arylation of Tertiary Carbon-Centered Radicals
  作者：Lianqian Wu、Fei Wang、Pinhong Chen、Guosheng Liu

  DOI：10.1021/jacs.8b13052

  日期：2019.2.6

  An enantioselective copper-catalyzed arylation of tertiary carbon-centered radicals, leading to quaternary all-carbon stereocenters, has been developed herein. The tertiary carbon-centered radicals, including both benzylic and nonbenzylic radicals, were produced by the addition of trifluoromethyl radical to α-substituted acrylamides, and subsequently captured by chiral aryl copper(II) species to give

  本文开发了一种对映选择性铜催化的叔碳中心基团芳基化，导致季全碳立体中心。叔碳中心自由基，包括苄基和非苄基自由基，是通过将三氟甲基自由基加成到 α-取代的丙烯酰胺中产生的，随后被手性芳基铜 (II) 物种捕获，以产生具有优异对映选择性的 C-Ar 键。重要的是，与叔碳自由基相邻的酰基酰胺基 (CONHAr) 基团对于不对称自由基偶联至关重要。该反应本身具有底物范围广、官能团相容性好、条件温和等特点。
• [EN] HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE FXR (NR1H4) CONTENANT DES GROUHYDROXY
  申请人：GILEAD SCIENCES INC

  公开号：WO2016096115A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds (1) which bind to the NR1 H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds (1) for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本发明涉及结合NR1 H4受体（FXR）并作为FXR激动剂的化合物（1）。本发明还涉及利用这些化合物（1）制备药物以治疗疾病和/或病况，通过这些化合物结合所述核受体，并涉及这些化合物的合成过程。
• Isoindole-imide compounds and compositions comprising and methods of using the same
  申请人：Muller W. George

  公开号：US20070049618A1

  公开（公告）日：2007-03-01

  This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  这项发明涉及异吲哚-亚胺化合物，以及它们的药物可接受的盐、溶剂化物、对映异构体和前药。这些化合物的使用方法和药物组合物已经公开。
• [EN] MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] MODULATEURS D'INDOLAMINE 2,3-DIOXYGÉNASE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017195149A1

  公开（公告）日：2017-11-16

  Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

  提供的是IDO抑制剂化合物，其化学式为I，以及它们的药用可接受盐，它们的药物组合物，它们的制备方法，以及它们在预防或治疗疾病中的用途。
• MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20090036422A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of formula wherein Ar, R 1 , R 2 , R 3 , R 4 , R 5 , n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.

  本发明涉及以下式的化合物 其中 Ar，R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，n，o和p如本文所定义 或其药用合适的酸盐、光学纯对映体、拉氏体或二对映异构体混合物。式I的化合物可用于治疗睡眠障碍，如睡眠呼吸暂停症、嗜睡症、失眠、睡眠障碍、时差综合征、昼夜节律紊乱或与神经系统疾病相关的睡眠障碍。